Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prilosec patent litigation

This article was originally published in The Tan Sheet

Executive Summary

New York federal court upholds validity of AstraZeneca's two formulation patents and rules that three of four companies involved in Rx omeprazole patent litigation - Andrx, Dr. Reddy's and Genpharm - infringe those patents. However, Schwarz Pharma's product does not infringe, Judge Barbara Jones says in Oct. 11 ruling. Decision is not expected to impact AstraZeneca/P&G's eventual OTC sale of the proton pump inhibitor. OTC Prilosec would carry a claim for prevention of frequent heartburn - which differs from the approved Rx indication - and is expected to garner three-year Hatch/Waxman exclusivity. P&G anticipates FDA approval of the OTC switch in first quarter of 2003...

Related Content

Dr. Reddy’s Stakes Claim In U.S. OTC Market With Leiner Deal





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts